Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm
21. November 2024 13:14 ET
|
KUEHN LAW, PLLC
NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Zentalis Pharmaceuticals, Inc. (NASDAQ:...
Zentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azenosertib Studies
16. September 2024 07:00 ET
|
ZENTALIS PHARMACEUTICALS
SAN DIEGO, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small...
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02. Januar 2024 16:49 ET
|
ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically...
Zentalis to Participate in Investor Call Focused on Ovarian Cancer with Gynecologic Oncology Key Opinion Leader Joyce F. Liu, M.D., MPH, Hosted by TD Cowen
09. November 2023 07:00 ET
|
ZENTALIS PHARMACEUTICALS
Investor call to be held on Friday, November 10th, at 10:00 a.m. ET Company also to participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 15th,...
Zentalis Pharmaceuticals to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
06. September 2023 07:00 ET
|
ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically...
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01. September 2023 16:37 ET
|
ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically...
Moore Kuehn, PLLC Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm
15. Dezember 2022 10:15 ET
|
Moore Kuehn
NEW YORK, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Zentalis Pharmaceuticals, Inc....
Moore Kuehn, PLLC Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm
22. September 2022 10:35 ET
|
Moore Kuehn
NEW YORK, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Zentalis Pharmaceuticals,...
Moore Kuehn, PLLC Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm
30. August 2022 10:06 ET
|
Moore Kuehn
NEW YORK, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Zentalis Pharmaceuticals, Inc....